145 related articles for article (PubMed ID: 36449939)
1. Impact of proper surgical treatment on the survival of patients with epithelial ovary cancer.
Faria FH; Lage APD; Rodrigues AN; Wainstein AJA
Rev Col Bras Cir; 2022; 49():e20223231. PubMed ID: 36449939
[TBL] [Abstract][Full Text] [Related]
2. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
4. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
5. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
6. Beyond post-operative readmissions: analysis of the impact of unplanned readmissions during primary treatment of advanced-stage epithelial ovarian cancer on long-term oncology outcome.
Huang D; Harrison R; Curtis E; Mirabadi N; Chen GY; Alexandridis R; Barroilhet L; Rose S; Hartenbach E; Al-Niami A
Int J Gynecol Cancer; 2023 May; 33(5):741-748. PubMed ID: 36808044
[TBL] [Abstract][Full Text] [Related]
7. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
8. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
10. Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
Horner W; Peng K; Pleasant V; Brackmann M; Ebott J; Gutfreund R; McLean K; Reynolds RK; Uppal S
Gynecol Oncol; 2019 Aug; 154(2):283-289. PubMed ID: 31196575
[TBL] [Abstract][Full Text] [Related]
11. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
Hiu S; Bryant A; Gajjar K; Kunonga PT; Naik R
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD007697. PubMed ID: 36041232
[TBL] [Abstract][Full Text] [Related]
12. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer.
Greer A; Gockley A; Manning-Geist B; Melamed A; Sisodia RC; Berkowitz R; Horowitz N; Del Carmen M; Growdon WB; Worley M
Int J Gynecol Cancer; 2021 Oct; 31(10):1341-1347. PubMed ID: 34429355
[TBL] [Abstract][Full Text] [Related]
13. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
[TBL] [Abstract][Full Text] [Related]
14. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
15. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
[TBL] [Abstract][Full Text] [Related]
16. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
[TBL] [Abstract][Full Text] [Related]
17. Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
Nasioudis D; Kahn R; Chapman-Davis E; Frey MK; Caputo TA; Witkin SS; Holcomb K
Gynecol Oncol; 2019 Aug; 154(2):401-404. PubMed ID: 31160074
[TBL] [Abstract][Full Text] [Related]
18. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
[TBL] [Abstract][Full Text] [Related]
19. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
20. Survival in stage IV ovarian cancer with increased use of debulking surgery and bevacizumab.
Verleye L; Castanares-Zapatero D; Devos C; De Gendt C; Silversmit G; Van Damme N; Hulstaert F; Thiry N; Neyt M
Int J Gynecol Cancer; 2023 Apr; 33(4):543-548. PubMed ID: 36604121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
